CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product...
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated,...
AV‑Comparatives triumphs at 2025 "Tiroler Innovationspreis 2025"
INNSBRUCK, Austria, Dec. 6, 2025 /PRNewswire/ -- The independent cybersecurity testing authority AV‑Comparatives has been awarded the top honor in the "Technical Innovation" category at the 2025 "Tiroler Innovationspreis" (Tyrolean innovation...
Hong Kong acclaimed artist Leo Wong debuts at Maison&Objet Intérieurs Hong Kong, showcase elegance and beauty of Hong Kong and Asian craftsmanship to the world
HONG KONG, Dec. 5, 2025 /PRNewswire/ -- Hong Kong ceramic artist Leo Wong (Wong Chun Yin) has been invited to participate in "Maison&Objet Interieurs Hong Kong", where his signature "Peony Pond" series will be presented in the "Design Factory"...
AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer
- Ovarian cancer remains an unmet medical need, and experts call for new strategies to define and treat platinum resistance in patients with advanced ovarian cancer[1],[2],[3] SINGAPORE, Dec. 5, 2025 /PRNewswire/ -- At an AbbVie-sponsored symposium...
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance The Phase 1 ragistomig study achieved its...
CKGSB Concludes 12th Women in Leadership Forum and Launches Report on Female Entrepreneurs Shaping China's Digital Economy
BEIJING, Dec. 4, 2025 /PRNewswire/ -- Cheung Kong Graduate School of Business (CKGSB) successfully held its 2025 Women in Leadership Forum on December 2, 2025, in Beijing. Now in its 12th year, the forum has become one of China's leading platforms...
Hyundai Motor, Kia's Robotics LAB and DEEPX Begin Commercialization for Next-Generation On-Device AI Robot Platform
SEOUL, South Korea, Dec. 3, 2025 /PRNewswire/ -- DEEPX, an ultra-low-power on-device AI semiconductor company, is unveiling a next-generation robot intelligence platform co-developed with Hyundai Motor and Kia's Robotics LAB. The controller platform...
Waterdrop Wins 2025 Global Best Case Brands Award, Empowering Inclusive Protection Through Technological Innovation
BEIJING, Dec. 3, 2025 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) was honored with the Global Best Case Brands Award at the 3rd International Conference on Management Change and Sustainable Development (MC&SD). Selected from more than 100...
Natural Field Releases "Ashwagandha White Paper" and Landmark Liposome Research Achievements at 2025 FTA (Food Research Exchange Super Ingredients Conference)
HANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Against the backdrop of the accelerated upgrading of the global functional nutrition industry, technology-driven ingredient enterprises are increasingly emerging as the core force of the industrial...